Levetiracetam Injection
Product Images NDC 68083-154

Levetiracetam in 0.82% Sodium Chloride Injection is a medication used for intravenous infusion only, containing 500mg of Levetiracetam in 100mL solution. It should be infused over a period of 15 minutes and not further diluted before use. The usual dosage should be referred to in the package insert. It is important to not use plastic containers in series connections. The medication comes in a single-dose, dual port bag and should be used promptly after removing the overwrap. It is recommended to store between 20-25°C (68-77°F). Manufactured by Gland Pharma Limited.*

Levetiracetam in 0.75% Sodium Chloride Injection is a prescription medicine that is meant to be used for intravenous infusion only. It contains 1,000 mg Levetiracetam (10 mg/mL), water for injection, 750 mg sodium chloride, 6.5 mg of glacial acetic acid and buffered at approximately pH 5.5 with glacial acetic acid and 164 mg sodium acetate trihydrate per 100 mL. The usual dosage is available in the package insert. This medicine should not be further diluted before use and caution must be taken not to use plastic containers in series connections. It should be used promptly once the overwrap is removed and stored at 20° to 25°C (68° to 77°F). The manufacturer of this medicine is GLAND PHARMA LIMITED in Hyderabad, India.*

This is a prescription-only medication called Levetiracetam, available in a 100 mL bag and is intended for intravenous infusion only. Each 100 mL contains 1,500 mg of Levetiracetam, 0.54% sodium chloride, water for injection, 7.5 mg of glacial acetic acid, and 164 mg sodium acetate trinyarate, buffered at pH 5.5. It is important not to use plastic containers in series connections and not to dilute the solution further. This medication should be stored at 20°C to 25°C and must be used promptly once the overwrap is removed. The usual dosage is stated in the package insert. The manufacturer is Gland Pharma Limited.*

The text describes the percentage of patients taking Placebo, Levetiracetam at 1000 mg/day, and Levetiracetam at 3000 mg/day, with the indication that the last two are statistically significant versus placebo. No further information is available.*

The text presents the results of a study on the effectiveness of Levetiracetam in treating a medical condition. Patients were either given a placebo or Levetiracetam at 1000mg/day or 2000mg/day. The study showed that both doses of Levetiracetam were statistically significant in comparison to the placebo group. However, there is no information about what medical condition was being treated.*

This is a chart depicting the percentage of patients in a study group who received either a placebo or 3000mg/day of Levetiracetam, a medication used to treat seizures. The chart shows that Levetiracetam was statistically significant in its effectiveness when compared to the placebo. However, without further context, it is unclear what the specific effects and outcomes of the study were.*

The chart shows the percentage of patients who responded to the treatment of Levetiracetam compared to the placebo. The study involved 84 patients who received a placebo and 79 patients who received Levetiracetam. The percentage of patients who responded to Levetiracetam was 72.2%, which was statistically significant compared to the placebo, which only had a response rate of 45.2%.*